The stock has a 36-month beta value of 1.24. Opinions on the stock are mixed, with 1 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for AIM is 3.14M, and at present, short sellers hold a 10.45% of that float. On February 12, 2026, the average trading volume of AIM was 1.25M shares.
AIM stock’s latest price update
AIM ImmunoTech Inc (AMEX: AIM)’s stock price has plunge by -13.51%relation to previous closing price of $0.98. Nevertheless, the company has seen a -20.03% plunge in its stock price over the last five trading sessions.
AIM’s Market Performance
AIM ImmunoTech Inc (AIM) has seen a -20.03% fall in stock performance for the week, with a -32.50% decline in the past month and a -46.31% plunge in the past quarter. The volatility ratio for the week is 30.43%, and the volatility levels for the past 30 days are at 13.32% for AIM. The simple moving average for the past 20 days is -27.61% for AIM’s stock, with a -79.18% simple moving average for the past 200 days.
AIM Trading at -33.78% from the 50-Day Moving Average
After a stumble in the market that brought AIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.65% of loss for the given period.
Volatility was left at 13.32%, however, over the last 30 days, the volatility rate increased by 30.43%.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AIM starting from Equels Thomas K, who purchase 41,000 shares at the price of $0.06 back on Apr 04 ’25. After this action, Equels Thomas K now owns 1,899,029 shares of AIM ImmunoTech Inc, valued at $2,583 using the latest closing price.
Rodino Peter W III, the COO, Secretary, Gen. Counsel of AIM ImmunoTech Inc, purchase 500 shares at $0.09 during a trade that took place back on Apr 04 ’25, which means that Rodino Peter W III is holding 401,762 shares at $44 based on the most recent closing price.
Stock Fundamentals for AIM
Current profitability levels for the company are sitting at:
- -129.33% for the present operating margin
- 0.19% for the gross margin
The net margin for AIM ImmunoTech Inc stands at -140.62%. The total capital return value is set at -9.98%. Equity return is now at value -3138.91%, with -165.08% for asset returns.
Based on AIM ImmunoTech Inc (AIM), the company’s capital structure generated -0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -5.53. The debt to equity ratio resting at -0.38. The interest coverage ratio of the stock is -26.19.
Currently, EBITDA for the company is -$16.49 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 24.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
To sum up, AIM ImmunoTech Inc (AIM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.